Immuneering Corp (IMRX)
| Market Cap | $227.97M-44.6% |
| Revenue (ttm) | n/a |
| Net Income | -$66.50M |
| EPS | -$0.92 |
| Shares Out | 64.76M |
| PE Ratio | n/a |
| Forward PE | -2.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,019,933 |
| Open | $3.70 |
| Previous Close | $3.71 |
| Day's Range | $3.48 - $3.78 |
| 52-Week Range | $3.35 - $8.48 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | $17.00(+382.95%) |
| Earnings Date | Oct 29, 2026 |
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Immuneering Corp Stock Analysis — InsiderScore
Immuneering Corp scored higher than 69% of companies evaluated by InsiderBuying, and ranked 24th out of 101 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Immuneering Corp bought $89.5K of stock across 1 purchase in the last 90 days, the largest of them $89.5K.
The average purchase added about 11% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IMRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IMRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMRX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IMRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple conference presentations and positive pancreatic cancer data support clinical progress, though no major catalyst or analyst action provided.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.25% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.15% |
| IWC | iShares Micro-Cap ETF | 0.05% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.02% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
Weight is the stock’s share of each fund’s holdings.
